-$0.55 Earnings Per Share Expected for Rhythm Pharmaceuticals Inc (RYTM) This Quarter
Wall Street brokerages forecast that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will post ($0.55) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings. The company is scheduled to issue its next earnings report on Tuesday, February 20th.
According to Zacks, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($1.64) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($1.54). For the next financial year, analysts forecast that the company will report earnings of ($2.05) per share, with EPS estimates ranging from ($2.37) to ($1.72). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Tuesday, November 14th. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($1.38).
Several large investors have recently modified their holdings of RYTM. Wells Fargo & Company MN bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth $131,000. American International Group Inc. bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth $161,000. The Manufacturers Life Insurance Company bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth $184,000. Metropolitan Life Insurance Co. NY bought a new position in shares of Rhythm Pharmaceuticals during the 4th quarter valued at $196,000. Finally, MetLife Investment Advisors LLC bought a new position in shares of Rhythm Pharmaceuticals during the 4th quarter valued at $287,000. 10.05% of the stock is currently owned by hedge funds and other institutional investors.
Rhythm Pharmaceuticals (RYTM) traded down $0.09 during midday trading on Wednesday, reaching $26.26. 68,806 shares of the company’s stock traded hands, compared to its average volume of 77,673. Rhythm Pharmaceuticals has a fifty-two week low of $21.38 and a fifty-two week high of $33.81.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2018/02/17/0-55-earnings-per-share-expected-for-rhythm-pharmaceuticals-inc-rytm-this-quarter.html.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.